Skip to main content
Back
Watch Compare

Autolus Therapeutics plc

Data quality: 100%
AUTL
Nasdaq Manufacturing Chemicals
$1.48
▼ $0.01 (-0.67%)
Mkt Cap: 393.89 M
Price
$1.48
Mkt Cap
393.89 M
Day Range
$1.45 — $1.54
52-Week Range
$1.11 — $2.70
Volume
1,822,728
Open $1.49
50D / 200D Avg
$1.48
0.11% above
50D / 200D Avg
$1.69
12.43% below

Quick Summary

Key Takeaways

Negative free cash flow of -302.61 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)644.94%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-93.98%
Below sector avg (-51.02%)
ROIC-34.70%
Net Margin-381.40%
Op. Margin-358.87%

Safety

Debt / Equity
N/A
Current Ratio6.19
Interest Coverage-7.38

Valuation

PE (TTM)
-1.37
Above sector avg (-1.98)
P/B Ratio1.48
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)
Metric Stock Sector Median
P/E -1.4 -2.0
P/B 1.5 5.1
ROE % -94.0 -51.0
Net Margin % -381.4 -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

ETFs Holding This Stock

CANC logo CANC Tema Oncology ETF
0.31% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 644.94% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 75.39 M Net Income (TTM) -287.53 M
ROE -93.98% ROA -41.58%
Gross Margin N/A Operating Margin -358.87%
Net Margin -381.40% Free Cash Flow (TTM) -302.61 M
ROIC -34.70% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 6.19
Interest Coverage -7.38 Asset Turnover 0.11
Working Capital 431.51 M Tangible Book Value 245.17 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.37 Forward P/E N/A
P/B Ratio 1.48 P/S Ratio 5.22
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -76.83%
Market Cap 393.89 M Enterprise Value 307.77 M
Per Share
EPS (Diluted TTM) -1.08 Revenue / Share 0.28
FCF / Share -1.14 OCF / Share -1.07
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 25.26% FCF Conversion 105.25%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 75.39 M 10.12 M — — —
Net Income -287.53 M -220.66 M -208.38 M -148.84 M -142.10 M
EPS (Diluted) -1.08 -0.86 -1.20 -1.57 -1.97
Gross Profit — — — — —
Operating Income -270.54 M -241.43 M -179.70 M -168.05 M -165.00 M
EBITDA — — — — —
R&D Expenses 117.69 M 138.44 M 130.48 M 141.99 M 134.79 M
SG&A Expenses 131.87 M 101.09 M — — —
D&A 8.30 M 7.55 M 6.57 M 7.42 M 8.46 M
Interest Expense 36.67 M 9.29 M 45.07 M 8.91 M 1.11 M
Income Tax 1.97 M 1.53 M -19,500.0 -24.37 M -23.89 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 589.07 M 782.73 M 375.38 M 490.27 M 405.56 M
Total Liabilities 410.94 M 355.40 M 263.91 M 191.60 M 92.24 M
Shareholders' Equity 178.13 M 427.33 M 111.47 M 298.67 M 313.32 M
Total Debt — — — — —
Cash & Equivalents 104.13 M 227.38 M 239.57 M 382.44 M —
Current Assets 435.92 M 660.93 M 275.30 M 425.77 M 346.95 M
Current Liabilities 73.44 M 60.74 M 44.74 M 46.37 M 28.55 M